Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E1301||ECOG||A Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With States III/IV Head and Neck Squamous Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|
|S0309||SWOG||Myeloma Specimen Repository Protocol Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-30607||CALGB||Randomized; Phase III; Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511; IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced; Stage IIIB/IV Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NCCTG-N06C6||NCCTG||A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-90202||CALGB||A Randomized Double-Blind; Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0250||GOG||A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297||Adult CIRB - Late Phase Emphasis||Completed|
|ASCT0631D||COG||A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors with and without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631||Pediatric CIRB||Completed|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-C-11||NSABP||A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients with Potentially Resectable Hepatic Colorectal Metastases||Adult CIRB - Late Phase Emphasis||Completed|